PHARMA - Relationships

Relationships Table

Entities - Color - Target Drug Disease Lo Med Hi
CCL4 5,638 Target Target Eotaxin-2/CCL24 19 1 0.00 -0.97 0.05 0.64
Ovarian Cancer 33,996 Disease Target Kallikrein-8 19 6 0.01 -0.83 0.32 0.64
CD68 6,424 Target Target AMAC-1 19 1 0.00 -0.97 0.05 0.64
CD68 6,424 Target Target Eotaxin-2/CCL24 19 1 0.00 -0.97 0.05 0.64
Skin Disease 6,955 Disease Target Eotaxin-2/CCL24 19 1 0.00 -0.97 0.05 0.64
Nausea 42,627 Disease Drug Amitiza (Lubiprostone)- FDA 19 6 0.01 -0.83 0.32 0.64
Diarrhea 51,986 Disease Drug Amitiza (Lubiprostone)- FDA 19 7 0.01 -0.79 0.37 0.63
Metastatic Breast Cancer 9,288 Disease Drug Aralen (Chloroquine)- FDA 19 1 0.00 -0.97 0.05 0.63
Benign Prostatic Hyperplasia 10,026 Disease Target Kallikrein-8 19 1 0.00 -0.97 0.05 0.63
Androgen Receptor 12,918 Target Drug Kaad-Cyclopamine 19 1 0.00 -0.97 0.05 0.62
Graft Versus Host Disease 15,741 Disease Target AMAC-1 19 1 0.00 -0.97 0.05 0.62
Chronic Pain 21,087 Disease Target Mu-Type Opioid Receptor 19 1 0.00 -0.97 0.05 0.61
Osteoporosis 46,215 Disease Target ALK Phos 19 2 0.00 -0.95 0.11 0.61
Dyspnea 24,781 Disease Drug Amitiza (Lubiprostone)- FDA 19 1 0.00 -0.97 0.05 0.60
Headache 50,687 Disease Drug Amitiza (Lubiprostone)- FDA 19 2 0.00 -0.95 0.11 0.60
Non Small Cell Lung Cancer 28,563 Disease Target Kallikrein-8 19 1 0.00 -0.97 0.05 0.60
Colon Cancer 30,064 Disease Target Complement Decay-Accelerating Factor 19 1 0.00 -0.97 0.05 0.60
Osteoarthritis 36,287 Disease Target ALK Phos 19 1 0.00 -0.97 0.05 0.60
Osteoarthritis 36,287 Disease Target Kallikrein-8 19 1 0.00 -0.97 0.05 0.60
CD4 112,219 Target Target Tegument Protein Vp16 19 3 0.00 -0.92 0.16 0.60
Poisoning 53,779 Disease Target ALK Phos 19 1 0.00 -0.97 0.05 0.59
CD4 112,219 Target Target Eotaxin-2/CCL24 19 2 0.00 -0.95 0.11 0.59
Prostate Cancer 71,064 Disease Target 464.1 19 1 0.00 -0.97 0.05 0.58
Prostate Cancer 71,064 Disease Target ALK Phos 19 1 0.00 -0.97 0.05 0.58
Prostate Cancer 71,064 Disease Target Kallikrein-8 19 1 0.00 -0.97 0.05 0.58
Renal Failure 73,993 Disease Target 464.1 19 1 0.00 -0.97 0.05 0.58
Renal Failure 73,993 Disease Target ALK Phos 19 1 0.00 -0.97 0.05 0.58
Infection 766,637 Disease Target Tegument Protein Vp16 19 10 0.00 -0.69 0.53 0.58
Pneumonia 81,521 Disease Target ALK Phos 19 1 0.00 -0.97 0.05 0.58
Anemia 81,663 Disease Target ALK Phos 19 1 0.00 -0.97 0.05 0.58
Lung Cancer 91,416 Disease Drug Kaad-Cyclopamine 19 1 0.00 -0.97 0.05 0.58
Lung Cancer 91,416 Disease Target Kallikrein-8 19 1 0.00 -0.97 0.05 0.58
Cancer 1,053,491 Disease Target Kallikrein-8 19 10 0.00 -0.69 0.53 0.57
CD4 112,219 Target Target Complement Decay-Accelerating Factor 19 1 0.00 -0.97 0.05 0.57
CD4 112,219 Target Target AMAC-1 19 1 0.00 -0.97 0.05 0.57
Arthritis 128,324 Disease Target Eotaxin-2/CCL24 19 1 0.00 -0.97 0.05 0.57
Arthritis 128,324 Disease Target Kallikrein-8 19 1 0.00 -0.97 0.05 0.57
Shock 134,031 Disease Target Tegument Protein Vp16 19 1 0.00 -0.97 0.05 0.57
Tuberculosis 146,217 Disease Target Eotaxin-2/CCL24 19 1 0.00 -0.97 0.05 0.57
Carcinoma 433,099 Disease Target Kallikrein-8 19 2 0.00 -0.95 0.11 0.56
Depression 220,092 Disease Target Mu-Type Opioid Receptor 19 1 0.00 -0.97 0.05 0.56
Diabetes 332,602 Disease Drug Kaad-Cyclopamine 19 1 0.00 -0.97 0.05 0.55
Diabetes 332,602 Disease Target 464.1 19 1 0.00 -0.97 0.05 0.55
Diabetes 332,602 Disease Target ALK Phos 19 1 0.00 -0.97 0.05 0.55
Cancer 1,053,491 Disease Drug Aralen (Chloroquine)- FDA 19 3 0.00 -0.92 0.16 0.55
Infection 766,637 Disease Target Eotaxin-2/CCL24 19 2 0.00 -0.95 0.11 0.55
Carcinoma 433,099 Disease Target 464.1 19 1 0.00 -0.97 0.05 0.54
Cancer 1,053,491 Disease Target 464.1 19 2 0.00 -0.95 0.11 0.54
Cancer 1,053,491 Disease Target ALK Phos 19 1 0.00 -0.97 0.05 0.53
Cancer 1,053,491 Disease Drug Amitiza (Lubiprostone)- FDA 19 1 0.00 -0.97 0.05 0.53